Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Neladalkib for ALK-positive lung cancer (non-small cell), previously treated

FDA decision
Nov 172026
Approved
November has 13 FDA decisions on our calendar, this one included. Before it, Adrabetadex on Nov 17th. After it, Deramiocel on Nov 22nd.
Approved
The FDA approved this application. Approval is the starting line, not the finish: our guide to what happens in the 90 days after a rare disease approval walks through specialty pharmacies, insurance review, and how families shorten the wait.

What the FDA decided on Neladalkib for ALK-positive lung cancer

The FDA approved Neladalkib for ALK-positive lung cancer (non-small cell), previously treated.

The FDA granted accelerated approval to Nelkarmi (neladalkib) on November 17, 2026, 10 days before its target date. It is for adults with ALK-positive non-small cell lung cancer that is locally advanced or has spread, after either alectinib as their only prior ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy.

In the ALKOVE-1 trial, tumors shrank in 49% of the 67 people who had taken only alectinib and in 32% of the 155 people who had taken 2 or more ALK inhibitors and chemotherapy. About half of those responses lasted a year or longer in both groups.

Nelkarmi is a pill taken once a day. The label warns about liver, kidney and eye problems, muscle enzyme rises and harm to an unborn baby. Accelerated approval means the FDA can require a further study to confirm the benefit. Nuvalent, now part of GSK, had not announced pricing or a support program when this was recorded.

Frequently asked questions

Has the FDA decided on Neladalkib?

The FDA has already decided. It approved the application.

Details: the outcome and what it means are at the top of this page.

Source: FDA approval notice, Nov 17 2026

What was Neladalkib approved for?

The FDA approved Nuvalent (GSK)'s NDA for Neladalkib in ALK-positive lung cancer (non-small cell), previously treated.

What to know: The FDA granted accelerated approval to Nelkarmi (neladalkib) on November 17, 2026, 10 days before its target date. It is for adults with ALK-positive non-small cell lung cancer that is locally advanced or has spread, after either alectinib as their only prior ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy. In the ALKOVE-1 trial, tumors shrank in 49% of the 67 people who had taken only alectinib and in 32% of the 155 people who had taken 2 or more ALK inhibitors and chemotherapy. About half of those responses lasted a year or longer in both groups. Nelkarmi is a pill taken once a day. The label warns about liver, kidney and eye problems, muscle enzyme rises and harm to an unborn baby. Accelerated approval means the FDA can require a further study to confirm the benefit. Nuvalent, now part of GSK, had not announced pricing or a support program when this was recorded.

How much will Neladalkib cost?

Trial Friend does not list a price for Neladalkib. What you pay depends on your insurance and on help from the drugmaker or a charity fund.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Neladalkib decision?

The FDA approved Neladalkib for ALK-positive lung cancer (non-small cell), previously treated on November 17, 2026.

Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

Where this outcome comes from

The outcome on this page comes from FDA approval notice, Nov 17 2026. This page rechecks against our calendar, which is re-verified daily.